Clinical Trial Update: IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

A phase 2 study evaluating pembrolizumab in combination with local tumor ablation for hepatocellular carcinoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: COMPLETED | Results posted: 2026-03-23